After reporting its unaudited fourth-quarter revenue, MedMen was up 4% in today's early morning trading. YTD (year-to-date), its stock is down 37.7% as of August 12. In January, two of MedMen's early investors filed a lawsuit alleging financial irregularities, but in June, they withdrew the suit and sought arbitration instead. The allegations seem to have led to a fall in MedMen stock. MedMen has underperformed its peers. Innovative Industrial Properties (IIPR), Aphria (APHA), and Canopy Growth (WEED) (CGC) are up 119.5%, 10.3%, and 18.8%, respectively, YTD. On August 8, IIPR reported an impressive second-quarter performance. Aphria also outperformed analysts' expectations in its latest earnings. Read about Aphria's fourth-quarter performance in Aphria Stock Rises on Earnings Beat.